KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Castle Biosciences (CSTL) Leases (2021 - 2025)

Castle Biosciences' Leases history spans 5 years, with the latest figure at $251000.0 for Q4 2025.

  • For Q4 2025, Leases fell 97.83% year-over-year to $251000.0; the TTM value through Dec 2025 reached $251000.0, down 97.83%, while the annual FY2025 figure was $251000.0, 97.83% down from the prior year.
  • Leases for Q4 2025 was $251000.0 at Castle Biosciences, down from $15.2 million in the prior quarter.
  • Across five years, Leases topped out at $15.5 million in Q2 2025 and bottomed at $91000.0 in Q4 2023.
  • The 5-year median for Leases is $11.6 million (2024), against an average of $9.6 million.
  • The largest annual shift saw Leases tumbled 99.25% in 2023 before it soared 12629.67% in 2024.
  • A 5-year view of Leases shows it stood at $229000.0 in 2021, then soared by 5219.21% to $12.2 million in 2022, then crashed by 99.25% to $91000.0 in 2023, then skyrocketed by 12629.67% to $11.6 million in 2024, then crashed by 97.83% to $251000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Leases are $251000.0 (Q4 2025), $15.2 million (Q3 2025), and $15.5 million (Q2 2025).